KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $92.4 million.

  • Esperion Therapeutics' Cash & Equivalents fell 36.12% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.4 million, marking a year-over-year decrease of 36.12%. This contributed to the annual value of $144.8 million for FY2024, which is 76.01% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Cash & Equivalents of $92.4 million as of Q3 2025, which was up 7.42% from $86.1 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Cash & Equivalents peaked at $226.6 million during Q1 2024, and registered a low of $82.2 million during Q4 2023.
  • For the 3-year period, Esperion Therapeutics' Cash & Equivalents averaged around $134.5 million, with its median value being $138.5 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 76.01% in 2024, then tumbled by 54.54% in 2025.
  • Esperion Therapeutics' Cash & Equivalents (Quarterly) stood at $208.9 million in 2021, then crashed by 40.27% to $124.8 million in 2022, then slumped by 34.08% to $82.2 million in 2023, then skyrocketed by 76.01% to $144.8 million in 2024, then crashed by 36.12% to $92.4 million in 2025.
  • Its last three reported values are $92.4 million in Q3 2025, $86.1 million for Q2 2025, and $114.6 million during Q1 2025.